[ad_1]
Dublin, February 24, 2021 (GLOBE NEWSWIRE) – The report “US HIV Drug Market, Dosage, Price, Sales Outlook 2021 – 2026” has been added to ResearchAndMarkets.com from offer.
“US Anti-HIV Drugs Market, Dosage, Price, Sales Outlook 2021 – 2026”, it is concluded that the research and development pipelines for anti-HIV drugs are growing at a high rate and on a more positive note, The success rate associated with available antiretrovirals continues to grow to historic levels.
Nonetheless, this prompts researchers to build a solid overall framework for clinical activity and ultimately results in new product launches in the years to come. It is estimated that future new products developed in the US bio-pharmaceutical companies and research center will also largely contribute to the average growth rate of the market.
The prepared research report provides an overview of the US anti-HIV drugs market, which includes areas of growth as well as channel prospect. In the research report, the impacts of new drug launches are described in relation to traditional drugs. In addition to this, the market research report also highlights several segments to watch out for in the coming years for their impact on the overall market growth and consumption rate.
It is observed that the pharmaceutical opportunities in the United States related to the anti-HIV drug market subsequently increase over time. The momentum that the United States has shown for HIV treatment is making the market a super growth asset. Hundreds of available therapies have successfully opened new windows to exploit immediate actions on the control of CD4 + T cells in the human body.
Although the US anti-HIV drug market has not achieved a comprehensive treatment regimen for patients, the efficiency with which US researchers have provided specific drugs and therapies that could improve health conditions is stunning by compared to other emerging markets of the world which are still adapting to the mutative nature of the virus. It is observed for the US anti-HIV drug market that the research and development activities found in the country are supposed to focus on large-scale market acceptance and expansion in a short period of time.
The US anti-HIV drug market will exceed $ 1 billion within a few years at an exponential compound annual growth rate. It is estimated that the main key market drivers will continue to develop in the United States. One of the main reasons for the sales growth rate in the United States is the high dynamics of exchange rates and the favorable dynamics of high potency antiretrovirals.
For the expanding anti-HIV drug market in the United States, total spending on bills is also increasing at a high compound annual growth rate. In addition to this, the net revenues of the manufacturers generated by the anti-HIV drugs market are also expected to increase by a high percentage. According to the research conducted, the overall expenditure for market growth is driven by a wide range of factors including an increased rate of adoption of new products.
In the United States, technological development is also a potential democratizing force, which further enables major American key players to enter the market. To drive the overall market, biopharmaceutical companies are also increasingly including several patient-centric approaches and strategies to drive certain organizational changes in the market and finally create a market capable of transducing the potential benefits for healthcare that could make the lives of patients infected with HIV. better compared to world markets.
Highlights of the report:
- US Anti-HIV Drug Market and Clinical Trial Overview
- Comprehensive Price and Dosage Analysis of Anti-HIV Drugs Approved for the US Market
- Anti-HIV drug patent calendar
- Dosage, formulation, patent, price overview by drug class
- 360-page data and analysis on all approved drugs on the market
Main topics covered:
1. US Anti-HIV Drugs Market – Prevalence and Statistics
2. Overview of the US anti-HIV drug market
2.1 Current market scenario
2.2 Clinical trials landscape
3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the United States – Brand and Generic Availability, Dosage Analysis, Patents, Price and Sales
3.1 Abacavir (Ziagen)
3.2 Emtricitabine (Emtriva)
3.3 Lamivudine (Epivir)
3.4 Tenofovir disoproxil fumarate (Viread)
3.5 Zidovudine (Retrovir)
3.6 Stavudine (Zerit)
3.7 Didanosine (Videx / Videx EC)
4. US Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) – Brand and Generic Availability, Dosage Analysis, Patents, Price and Sales
4.1 Doravirine (Pifeltro)
4.2 Efavirenz (Sustiva)
4.3 Etravirine (Intelence)
4.4 Rilpivirine (Edurant)
4.5 Nevirapine (Viramune / Viramune XR)
5. US Protease Inhibitors (PIs) – Brand and Generic Availability, Dosage, Patent and Price Analysis
5.1 Atazanavir (Reyataz)
5.2 Darunavir (Prezista)
5.3 Fosamprenavir (Lexiva)
5.4 Ritonavir (Norvir)
5.5 Saquinavir (Invirase)
5.6 Tipranavir (Aptivus)
5.7 Nelfinavir (Viracept)
5.8 Amprenavir (Agenerase)
5.9 Indinavir (Crixivan)
6. US Fusion Inhibitors – Brand and Generic Availability, Dosage, Patent and Price Analysis
6.1 Enfuvirtide (Fuzeon)
7. US CCR5 Antagonists – Brand and Generic Availability, Dosage, Patents, Price and Sales Analysis
7.1 Maraviroc (Selzentry)
8. US Integrase Inhibitors – Brand and Generic Availability, Dosage, Patent, Price and Sales Analysis
8.1 Dolutegravir (Tivicay)
8.2 Raltegravir (Isentress / Isentress HD)
9. US Attachment Inhibitors – Brand and Generic Availability, Dosage, Patents, Price and Sales Analysis
9.1 Ibalizumab-Uiyk (Trogarzo)
9.2 Fostemsavir (Rucobia)
10. US Pharmacokinetic Enhancers – Analysis of Availability, Dosage, Patents and Prices
10.1 Cobicistat (Tybost)
11. Combination Anti-HIV Drugs in the United States – Brand and Generic Availability, Analysis of Dosage, Patents, Price and Sales
11.1 Abacavir / Lamivudine (Epzicom)
11.2 Abacavir / Dolutegravir / Lamivudine (Triumeq)
11.3 Abacavir / Lamivudine / Zidovudine) Trizivir
11.4 Atazanavir / Cobicistat (Evotaz)
11.5 Bictegravir / emtricitabine / tenofovir alafenamide (Biktarvy)
11.6 Cobicistat / Darunavir (Prezcobix)
11.7 Cobicistat / Darunavir / Emtricitabine / Tenofovir (Symtuza)
11.8 Dolutegravir / Lamivudine (Dovato)
11.9 Dolutegravir / Rilpivirine (Juluca)
11.10 Doravirine / Lamivudine / Tenofovir (Delstrigo)
11.11 Efavirenz / Emtricitabine / Tenofovir (Atripla)
11.12 Efavirenz / Lamivudine / Tenofovir disoproxil fumarate (Symfi / Simfi Lo)
11.13 Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate (Genvoya)
11.14 Cobicistat / Elvitegravir / Emtricitabine / Tenofovir (Stribild)
11.15 Emtricitabine / Rilpivirine / Tenofovir Alafenamide (Odefsey)
11.16 Emtricitabine / Rilpivirine / Tenofovir (Complera)
11.17 Emtricitabine / Tenofovir Alafenamide (Descovy)
11.18 Emtricitabine / Tenofovir (Truvada)
11.19 Lamivudine / Tenofovir
11.20 Lamivudine / Zidovudine (Combivir)
11.21 Lopinavir / Ritonavir (Kaletra)
11.22 Cabotegravir / Rilpivirine (Cabenuva)
11.23 Emtricitabine / nelfinavir / tenofovir oral kit
11.24 Emtricitabine / lopinavir / ritonavir / tenofovir oral kit
12. Competitive landscape
12.1 AbbVie
12.2 AstraZeneca plc
12.3 Boehringer Ingelheim
12.4 Bristol Myers Squibb
12.5 Gilead
12.6 GlaxoSmithKline plc
12.7 Janssen Pharmaceuticals
12.8 Merck
12.9 Pfizer
12.10 Rock
12.11 Sun Pharma
12.12 ViiV Healthcare
For more information on this report, visit https://www.researchandmarkets.com/r/a2gm6k
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Source link
